Intensity Therapeutics, Inc.

The momentum for this stock is not very good. Intensity Therapeutics, Inc. is not a good value stock. Intensity Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Intensity Therapeutics, Inc..
Log in to see more information.
INTS Fundamental Data by TradingView

News

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR...\n more…

Intensity Therapeutics Doses First U.S. Patient in Phase 3 Study for Metastatic Sarcoma Treatment
Intensity Therapeutics Doses First U.S. Patient in Phase 3 Study for Metastatic Sarcoma Treatment

Proactive Investors - UK Intensity Therapeutics Doses First U.S. Patient in Phase 3 Study for Metastatic Sarcoma Treatment...\n more…

INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024
INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nINTS stock results show that Intensity Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update...\n more…

Intensity Therapeutics doses first patient in Phase 3 sarcome study
Intensity Therapeutics doses first patient in Phase 3 sarcome study

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

PR Newswire Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma Intensity Therapeutics, Inc. Announces First...\n more…